Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a ...
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs ...
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score = 20 and key ...
This document explains the key points of the latest 2026 AHA/ACC guidelines for the treatment of pulmonary embolism (PE). A major change is that the use of low-molecular-weight heparin is now more ...
Heart failure (HF) remains a pressing health concern, with rising prevalence globally. Subjectivity and ambiguity in the definition of HF and its antecedent stages have limited research, global ...
One patient dies and nearly half need further surgery after returning to the UK, largest-ever BAAPS study reveals Britons chasing cut-price cosmetic surgery abroad are returning home with serious ...
Founded on July 3, 1946, SVS celebrates its legacy of supporting vascular surgeons, strengthening the specialty and ...
WHO's latest report shows that AI is already improving diagnosis, hospital efficiency and patient care across seven countries, but its success depends on strong governance, high-quality data, skilled ...
Advanced medical AI systems outperformed doctors in controlled diagnostic tests, but researchers caution they remain unproven in real-world healthcare.
(Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy ® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), ...
India Today on MSN
AI beats doctors in major medical tests, but there is a catch
Two advanced AI medical systems have outperformed doctors in key diagnosis and treatment-planning tests, according to new research. While the results are promising, researchers say the tools are still ...
The US Department of Health and Human Services is requesting revisions to the labels on testosterone replacement therapies for men after reviewing new data and evidence on their safety and benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results